Chul Kim
Physician · MedStar Health
Credentials: · · · · · ·
History
- 2025–Present
- 2003–2007
Doctor of Medicine
Research
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study
The Lancet Oncology · 2018 · 351 citations
Systematic review or meta-analysis · JAMA Oncology · 2019 · 187 citations
Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer
Molecular Cancer Therapeutics · 2021 · 184 citations
29 papers
- GG
13 papers
11 papers · 1 as a fellow
- MN
11 papers
10 papers
9 papers
9 papers
- UG
Udayan Guha
8 papers
Grants
- 2019–2027
National Capital Area (NCA) NCI Community Oncology Research Program (NCORP)
National Cancer Institute · UG1
PI · $1M · Georgetown University
Clinical trials
- 2024–2027
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
Principal investigator · Recruiting · Phase 2
Georgetown University
- 2024–2027
MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer
Principal investigator · Active not recruiting · Phase 2
Georgetown University
- 2017–2020
Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer
Principal investigator · Completed · Phase 1, Phase 2
Georgetown University
- 2020–2027
Study chair · Recruiting · Phase 2
Georgetown University